Inhibition of squalene synthase in vitro by 3-(biphenyl-4-yl)-quinuclidine

Biochemical Pharmacology

Volumn 51, Issue 11, 1996, Pages 1489-1501

  Ward, Walter H J ^a   Holdgate, Geoffrey A ^a   Freeman, Susan ^a   McTaggart, Fergus ^a   Girdwood, Pauline A ^a   Davidson, Robert G ^a   Mallion, Keith B ^a   Brown, George R ^a   Eakin, M Allan ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Anticholesterolemic agents; Atherosclerosis; Enzyme inhibitors; Hypercholesterolemia; Quinuclidines; Squalene synthase

Indexed keywords

3 (BIPHENYL 4 YL)QUINUCLIDINE; GERANYLTRANSFERASE; HYPOCHOLESTEROLEMIC AGENT; QUINUCLIDINE DERIVATIVE; SQUALENE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERCHOLESTEROLEMIA; NONHUMAN; PRENYLATION; PRIORITY JOURNAL;

ANIMALS; BINDING SITES; CALLITHRIX; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; KINETICS; MICROSOMES, LIVER; QUINUCLIDINES; RATS; SENSITIVITY AND SPECIFICITY;

EID: 0030049352     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00090-1     Document Type: Article

References (53)

1. Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994.
2. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Ruthrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J and Springer J, Mevalonin: a highly potent competitive inhibitor of hydroxymethyl glutaryl-coenzyme A reductase and a cholesterol lowering agent. Proc Natl Acad Sci USA 77: 3957-3961, 1980.
3. Davey-Smith G, Song F and Sheldon TA, Cholesterol lowering and mortality - the importance of considering initial level of risk. BMJ 306: 1367-1373, 1993.
4. Goldstein JL and Brown MS, Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
5. Poulter CD and Rilling HC, Conversion of farnesyl pyrophosphate to squalene. In: Biosynthesis of isoprenoid compounds (Eds Porter JW and Spurgeon SL), vol. 1, pp 413-441. Wiley, New York, 1981.
6. Kornhurst DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germerhausen JI and Alberts AW, Toxicity of the HMG-CoA reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 248: 498-505, 1989.
7. Folkers K, Langsjoen P, Willis R, Richardson P, Xia L-J, Ye C-Q and Tamagawa H, Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 87: 8931-8943, 1990.
8. Gonzalez-Pacanowska D, Arison A, Havel CM and Watson JA, Isopentenoid synthesis in isolated embryonic Drosophila cells. J Biol Chem 263: 1301-1306, 1988.
9. Ciosek CP, Magnin DR, Harrity TW, Logan JVH, Dickson JK, Gordon EM, Hamilton KA, Jolibois KG, Kunselman LK, Lawrence RM, Mookhtiar KA, Rich JC, Slusarchyk DA, Sulsky RB and Biller SA, Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem 268: 24832-24837, 1993.
10. Thelin A, Peterson E, Hutson JL, McCarthy AD, Ericsson J, Effect of squalestatin 1 on the biosynthesis of the mevalonate pathway lipids. Biochem Biophys Acta 1215: 245-249, 1994.
11. Stamellos KD, Shackelford JE, Shechter I, Jiang G, Conrad D, Keller G-A and Krisnas SK, Subcellular localisation of squalene synthase in rat hepatic cells. Biochemical and immunochemical evidence. J Biol Chem 268: 12825-12836, 1993.
12. Jennings SM, Tsay YH, Fisch TM and Robinson GW, Molecular cloning and characterisation of the yeast gene for squalene synthetase. Proc Natl Acad Sci USA 88: 6038-6042, 1991.
13. McKenzie TL, Jiang G, Straubhaar JR, Conrad DG and Shechter I, Molecular cloning, expression and characterization of the cDNA for rat hepatic squalene synthase. J Biol Chem 267: 21638-21674, 1992.
14. Summers C, Karst F and Charles AD, Cloning, expression and characterisation of the cDNA encoding human hepatic squalene synthase, and its relationship to phytoene synthase. Gene 136: 185-192, 1993.
15. Robinson GW, Tsay YH, Kienzle BK, Smithonroy CA and Bishop RW, Conservation betwen human and fungal squalene synthetases - similarities in structure, function and regulation. Mol Cell Biol 13: 2706-2717, 1993.
16. Jiang G, McKenzie TL, Conrad DG and Shechter I, Transcriptional regulation by lovastatin and 25-hydroxycholesterol in HepG2 cells and molecular cloning and expression of the cDNA for human hepatic squalene synthase. J Biol Chem 268: 12818-12824, 1993.
17. Shechter I, Kunger B, Rucker ML, Engstrom RG, Spirito JA, Islam MA, Boettcher BR and Weinstein DB, Solubilization, purification and characterization of a truncated form of rat hepatic squalene synthetase. J Biol Chem 267: 8628-8635, 1992.
18. LoGrasso PV, Soltis DA and Boettcher BR, Overexpression, purification and kinetic characterisation of a carboxy-terminal truncated yeast squalene synthetase. Arch Biochem Biophys 307: 193-199, 1993.
19. Zhang D, Jennings SM, Robinson GW and Poulter CD, Yeast squalene synthase: expression, purification and characterisation of soluble recombinant enzyme. Arch Biochem Biophys 304: 133-143, 1993.
20. Mookhtiar KA, Kalinowski SS, Zhang D and Poulter CD, Yeast squalene synthase. A mechanism for addition of substrates and activation by NADPH. J Biol Chem 269: 11201-11207, 1994.
21. Biller SA, Forster C, Gordon EM, Harrity T, Scott WA and Ciosek CP (1988) Isoprenoid (phosphinylmethyl)phosphonates as inhibitors of squalene synthetase. J Med Chem 31: 1869-1871, 1988.
22. Biller SA, Forster C, Gordon EM, Harrity T, Rich LC, Marretta J and Ciosek CP, Isoprenyl phosphinylformates: new inhibitors of squalene synthetase. J Med Chem 34: 1912-1914, 1991.
23. Biller SA, Sofia MJ, De Lange B, Forster C, Gordon EM, Harrity T, Rich LC and Ciosek CP, The first potent inhibitor of squalene synthase: a profound contribution of an ether oxygen to inhibitor-enzyme interaction. J Amer Chem Soc 113: 8522-8524, 1991.
24. Baxter A, Fitzgerald BJ, Hutson JL, McCarthy AD, Motteram JM, Ross BC, Sapra M, Snowden MA, Watson NS, Williams RJ and Wright C, Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J Biol Chem 267: 11705-11708, 1992.
25. Bergstrom JD, Kurtz MM, Rew DJ, Amend AM, Karkas JD, Bostedor RG, Bansal VS, Dufresne C, VanMiddlesworth FL, Henses OD, Liesch JM, Zink DL, Wilson KE, Onishi J, Milligan JA, Bills G, Kaplan L, Nallin Omstead M, Jenkins RG, Huang L, Meinz MS, Quinn L, Burg RW, Kong YL, Mochales S, Mojena M, Martin I, Pelaez F, Diez MT and Alberts AW, Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci USA 90: 80-84, 1993.
26. McTaggart F, Brown GR, Davidson RG, Freeman S, Holdgate GA, Mallion KB, Mirrlees DJ, Smith GJ and Ward WHJ, Inhibition of squalene sythase of rat liver by novel 3' substituted quinuclidines. Biochem Pharmacol 51: 1477-1487, 1996.
27. Delpech B and Khuong-Huu Q, Convenient two-step synthesis of substituted 1-azaadamantanes from α-pinene. J Organic Chem 43: 4898-4900, 1978.
28. Brown GR, Mallion KB, Harrison PJ and Harrison A, Biphenylquinuclidines, useful as squalene synthetase inhibitors. International Patent: Publication Number WO 93/09115, 1993.
29. Leatherbarrow RJ, GraFit (Version 3.01). Erithacus Software Ltd, Staines, U.K., 1992.
30. Mannervik B, Regression analysis, experimental error, and statistical criteria in the design and analysis of experiments for discrimination between rival kinetic models. Meth Enzymol 87: 370-390, 1982.
31. Segel IH, Enzyme Kinetics. Behaviour and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. John Wiley, New York, 1975.
32. Kenakin TA, Analysis of dose-response data. In: Pharmacological analysis of drug-receptor interaction, pp 176-220. Raven Press, New York, 1993.
33. Williams JW and Morrison JF, The kinetics or reversible tight binding inhibition. Meth Enzymol 63: 437-467, 1979.
34. Cleland, WW, Statistical analysis of enzyme kinetic data. Meth Enzymol 63: 103-138, 1979.
35. Morrison JF and Walsh CT, The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol 61: 201-301, 1988.
36. Goldstein A, The mechanism of enzyme-inhibitor-substrate interactions. J Gen Physiol 27: 529-580, 1944.
37. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE and Perrone MH, Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33: 1657-1663, 1992.
38. Agnew W and Popjàk G, Squalene synthetase. Stoichiometry and kinetics of presqualene pyrophosphate and squalene biosynthesis by yeast microsomes. J Biol Chem 253: 4566-4573, 1978.
39. Sasiak K and Rilling HC, Purification to homogeneity and some properties of squalene synthetase. Arch Biochem Biophys 260: 622-627, 1988.
40. Soltis DA, McMahon G, Caplan SL, Dudas DA, Chamberlin HA, Vattay A, Dottavio D, Rucker ML, Engstrom RG, Cornell-Kennon SA and Boettcher BR, Expression, purification and characterisation of the human squalene synthase: use of yeast and baculoviral systems. Arch Biochem Biophys 316: 713-723, 1995.
41. Dugan RE and Porter JW, Hog liver squalene synthetase: the partial purification of the particulate enzyme and kinetic analysis of the reaction. Arch Biochem Biophys 152: 28-35, 1972.
42. Fersht AR, Enzyme Structure and Mechanism. 2nd Ed. WH Freeman and Company, New York, 1985.
43. Lindsey S and Harwood HJ, Inhibition of mammalian squalene synthetase activity by zaragozic acid A is a result of competitive inhibition followed by mechanism-based irreversible inactivation. J Biol Chem 270: 9083-9096, 1995.
44. Cohen LH, Griffioen M, Van Roermund CWT and Wanders RJA, Subcellular localisation of squalene synthase in human hepatoma cell line HepG2. Biochim Biophys Acta 1126: 114-118, 1992.
45. Ericsson J, Appelvist E-L, Thelin A, Chojnacki T and Dallner G, Isoprenoid biosynthesis in rat liver peroxisomes. Characterisation of cis-prenyltransferase and squalene synthetase. J Biol Chem 267: 18708-18714, 1992.
46. Keller RK, Cannons A, Vilsaint F, Zhao Z and Ness GC, Identification and regulation of squalene synthetase mRNA. Arch Biochem Biophys 302: 304-306, 1993.
47. Poulter CD, Capson TL, Thompson MD and Bard RS, Squalene synthetase. Inhibition by ammonium analogues of carbocationic intermediates in the conversion of presqualene diphosphate to squalene. J Amer Chem Soc 111: 3734-3739, 1989,
48. Bruenger E and Rilling HC, Determination of isopentenyl diphosphate and farnesyl diphosphate in tissue samples with a comment on secondary regulation of polyisoprenoid biosynthesis. Anal Biochem 173: 321-327, 1988.
49. Beytia E, Qureshi AA and Porter JW, Squalene synthase. III Mechanism of action. J Biol Chem 248: 1856-1867, 1973.
50. Hasumi K, Tachikawa K, Sakai K, Murakawa S, Yoshikawa N, Kumazawa S and Endo A, Competitive inhibition of squalene synthetase by squalestatin I. J Antibiot 46: 689-691, 1993.
51. Shechter L and Bloch K, Solubilization and purification of trans-farnesyl pyrophosphate-squalene synthetase. J Biol Chem 246: 7690-7676, 1971.
52. Wilson DK, Tarle I, Petrash JM and Quiocho FA, Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc Natl Acad Sci USA 90: 9847-9851, 1993.
53. Cook PN, Ward WHJ, Petrash JM, Mirrlees DJ, Sennitt CM, Carey F, Brittain DR, Tuffin DP and Howe R, Kinetic characteristics of ZENECA ZD5522, a potent inhibitor of human and bovine lens aldose reductase. Biochem Pharmacol 49: 1043-1049, 1995.